Fluconazole Tablets - SPE2D2-26-D-0003
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-26-D-0003
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
The Defense Logistics Agency (DLA) Troop Support has issued an award notice for the procurement of Fluconazole Tablets under contract number SPE2D2-26-D-0003. This award follows a solicitation process initiated under SPE2D2-25-R-0009, reflecting the agency’s ongoing commitment to ensuring the availability of critical pharmaceutical products for federal requirements.
The scope of this procurement centers on the supply of Fluconazole Tablets, a widely used antifungal medication, to support the medical needs of federal entities. The awarded contract is classified under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further identified by Product Service Code 6505, denoting Drugs and Biologicals. The place of performance for this contract is Hauppauge, New York, indicating that manufacturing, distribution, or fulfillment activities will be based in this location.
DLA Troop Support, a federal office responsible for providing medical and pharmaceutical supplies to the military and other government agencies, serves as the contracting entity for this award. The agency’s role ensures that the procured pharmaceuticals meet stringent quality and regulatory standards, supporting the health and readiness of service members and other federal beneficiaries.
Key requirements and objectives of this procurement include the reliable production and timely delivery of Fluconazole Tablets in accordance with federal specifications. Contractors are expected to adhere to all applicable manufacturing, packaging, and quality assurance standards as mandated by federal regulations and DLA guidelines. The intended outcome is to maintain a consistent and secure supply chain for this essential medication, thereby supporting uninterrupted medical care across federal facilities.
The notice provides primary and secondary points of contact for further information: Courtney Hunter ([email protected], (445) 737-3585) and Jason C. Wray ([email protected], (445) 737-6304). Interested parties can reference the official award notice and related documentation via the SAM.gov opportunity ID 3ae1c9b209f94180987ab1f0385b72f5.
This award notice is currently active and was posted on March 11, 2025. Contractors evaluating similar opportunities should note the focus on pharmaceutical manufacturing capabilities, compliance with federal standards, and the ability to deliver to the specified location in Hauppauge, New York. No specific set-aside requirements or special considerations are indicated in the provided information.
For additional details and to review any available attachments, contractors are encouraged to visit the official notice at https://sam.gov/opp/3ae1c9b209f94180987ab1f0385b72f5/view.